Weekly Investment Analysts’ Ratings Updates for Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (NASDAQ: GLUE) has recently received a number of price target changes and ratings updates:

• 8/4/2026 – Monte Rosa Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/3/2026 – Monte Rosa Therapeutics had its price target lowered by Wedbush from $37.00 to $27.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – Monte Rosa Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 7/27/2026 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 7/27/2026 – Monte Rosa Therapeutics was given a new $25.00 price target by Jefferies Financial Group Inc..
• 7/6/2026 – Monte Rosa Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/30/2026 – Monte Rosa Therapeutics had its price target raised by Guggenheim from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Monte Rosa Therapeutics had its price target raised by Guggenheim from $30.00 to $35.00. They now have a “buy” rating on the stock.

Insider Activity at Monte Rosa Therapeutics

In other news, insider Sharon Townson sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the transaction, the insider owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. This represents a 8.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Filip Janku sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $21.42, for a total value of $642,600.00. Following the completion of the transaction, the insider directly owned 59,992 shares in the company, valued at $1,285,028.64. The trade was a 33.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 81,778 shares of company stock worth $1,768,581 in the last quarter. Corporate insiders own 6.40% of the company’s stock.

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.